Podcasts about pharmd

On this episode, we define major depressive disorder (MDD) and describe its clinical presentations, diagnostic criteria, etiologies, and pathophysiology. We also evaluate current guidelines and evidence-based treatment strategies for managing major depression, including pharmacological and nonpharmacological interventions. We then compare and contrast the efficacy, safety profiles, and appropriate use of antidepressant therapies, psychotherapy modalities, and adjunctive treatments in managing depression. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Not gonna give much of an introduction here because this is a short bonus level set, but I did just wanna call everyone's attention to the "arms race" created by our status quo purchasing and selling of many things, pharmaceuticals included. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For example, raise the list price of a drug to maximize rebates, because the higher the list, the bigger the discount you can give, which then exacerbates patient affordability because coinsurance is often based on list price. But then Pharma starts offering co-pay cards, which messes up the whole PBM (pharmacy benefit manager) plan to drive patients to their highest-rebate products (ie, the most profitable products). So then maximizers and accumulators enter the chat, and prior auths ramp up because plans start having to raise premiums after enough 340B drugs with high lists and no rebates, and then there's no cost containment and raise deductibles and around and around we go. Meanwhile, is this drug fundamentally worth the list price or even the net price? Is it an effective drug? What's the right price to be paying for this drug? Should be the operative question, right? Just like what's the quality and appropriateness of any medical service? Maybe we should just quit it and just pay for value. And with that, let me introduce Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review), and I will let Sarah tell the rest of the story. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Payerset; Aventria Health Group; Dea Belazi, PharmD, MPH; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   02:28 What is ICER? 02:47 What does the Institute for Clinical and Economic Review do? 05:09 The importance of still showing up, even when others don't understand or disagree. 06:51 EP293 ("Game Theory Gone Wild") with Dea Belazi, PharmD, MPH. 09:04 Why it's important to think about population health and how our choices impact affordability for everyone.   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #ICER and the status quo of #pharmaceuticaldrug #pricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl  

Tim & Tim discuss how to handle a windfall or inheritance with clarity emotionally, financially, and strategically during the biggest wealth transfer in U.S. history. This episode is brought to you by the American Pharmacists Association (APhA). Episode Summary Handling a windfall or inheritance isn't just about the money—it's an emotional, relational, and identity-level shift. Whether it's an inheritance, equity payout, stock options vesting, or another financial surprise, the "right" next step can feel overwhelming. Many people think the challenge is how to invest a large sum… but the real challenge often begins much earlier: Who am I now that money is no longer the limiting factor? In this episode, Tim Ulbrich, PharmD, and Tim Baker, CFP®, RICP®, RLP® break down how to prepare for, navigate, and thoughtfully plan through sudden wealth. They talk about the emotional side of receiving money, how to avoid rushed decisions, the importance of building the right team, tax considerations, and how to align a windfall with your goals, values, and relationships. With the largest wealth transfer in U.S. history underway, this is a conversation every generation needs to hear. If you've received a windfall, expect one, or simply want to understand how to handle one wisely, this episode will help you slow down, think clearly, and make decisions you won't regret. What you'll learn in this episode: Why sudden wealth creates emotional, identity, and relational shifts—not just financial ones The most common types of windfalls and why they require different planning strategies How to avoid rushed decisions and use a "90-day pause" to regain clarity The key professionals you need on your team before making major moves How taxes, investment priorities, and giving strategies change when a windfall enters the plan Mentioned on the Show Mom and Dad, We Need to Talk by Cameron Huddleston Cerulli Associates "Great Wealth Transfer" data "Die With Zero" by Bill Perkins YFP Episode: 5 Key Questions to Ask Before Hiring a Financial Planner

Claudin 18.2 is a novel biomarker for advanced gastric and gastroesophageal junction cancer. Patients who test positive for claudin 18.2 may be candidates for the monoclonal antibody, zolbetuximab, which directly targets this biomarker. In this episode, CANCER BUZZ speaks with Manish A. Shah, MD, FASCO, director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, about how claudin 18.2 is shaping treatment decisions and some of the clinical trials pursuing more information about the potential for this biomarker. CANCER BUZZ also speaks with Sasha Watson, PharmD, outpatient medical oncology clinical pharmacist at Sylvester Comprehensive Cancer Center, about the importance of engaging the whole multidisciplinary team in biomarker testing for optimal patient outcomes.   "I often talk to my gastroenterologist and ask them to get more than 1 biopsy to make sure that we have enough tissue for now and even in the future." - Manish A. Shah, MD, FASCO Instead of lumping all gastric cancers into one group, we use these biomarkers to split them out... We have more refined and tailored treatments for patients with gastroesophageal adenocarcinoma based on these biomarkers." - Manish A. Shah, MD, FASCO "Nurses in the infusion center are a huge help that we absolutely need, and administering this treatment would be very difficult if we didn't have scaled and experienced nurses here." - Aleksandra (Sasha) Watson, PharmD "What I see is just a lot of patients having hope—some new part of their cancer that we can target with a drug that we previously didn't have any options for." - Aleksandra (Sasha) Watson, PharmD   Guests:               Manish A. Shah, MD, FASCO  Director, Gastrointestinal Oncology Program Weill Cornell Medicine New York, NY Aleksandra (Sasha) Watson, PharmD  Outpatient Medical Oncology Clinical Pharmacist (GI + Sarcoma) Sylvester Comprehensive Cancer Center Miami, FL Resources ACCC Biomarkers Webpage ACCCBuzz Blog: Importance of Biomarker Testing, Patient Goals and Education When Treating Gastric Cancer

Send us a textDid you know that someone needs blood in the United States every two seconds? Whether it's for surgeries, cancer treatment, traumatic injuries or something else, your blood donation could help save a life. Suzanne Felton, Laboratory manager at St. Luke's, and Adam Wilcox, St. Luke's Clinical Pharmacy manager and a frequent blood donor, join Dr. Arnold to discuss blood donation.If you are interested in donating blood, visit lifeservebloodcenter.org to schedule your donation appointment. Do you have a question about a trending medical topic? Ask Dr. Arnold! Submit your question and it may be answered by Dr. Arnold on the podcast! Submit your questions at: https://www.unitypoint.org/cedarrapids/submit-a-question-for-the-mailbag.aspxIf you have a topic you'd like Dr. Arnold to discuss with a guest on the podcast, shoot us an email at stlukescr@unitypoint.org.

In this special Giving Tuesday episode, Ginger talks with Chuck Akanegbu, PharmD, a PGY1 resident and longtime NCODA PSO leader, whose involvement in the student community led to something bigger than he ever expected: donating stem cells through the National Marrow Donor Program (NMDP).Chuck reflects on how the PSO shaped his interest in oncology, what leadership taught him, and how he went from supporting donor drives as a student to becoming a donor himself. He breaks down the donation process in a straightforward way and shares how the experience is shaping his approach as a future oncology pharmacist.It's a timely reminder of what Giving Tuesday represents at NCODA: showing up for others, supporting patients and peers, and taking action when you have the chance to make an impact.Learn more about NMDP here.

Jami Mann, PharmD, MBA, is the Executive Director of Virtual Care Services at UNC Health. Dr. Mann has a pharmacy background - I was fortunate enough to serve as one of her preceptors in residency - and then went outside of pharmacy 5 years ago to lead virtual care for UNC Health. You'll hear about her path along with how virtual care fares in the post-COVID world. It will get your wheels turning as mine did on how we can further our virtual care offerings to expand care overall. We also talk about leadership and how to utilize your skill sets to lead an unchartered area and do it through authenticity. It's an episode you don't want to miss!

Recent FDA actions have brought renewed attention to leucovorin as a potential treatment for managing symptoms associated with autism spectrum disorder. This course explores the clinical distinctions between autism and cerebral folate deficiency, reviews key evidence behind leucovorin use, and outlines counseling considerations relevant to pharmacy practice. You will gain clarity on this complex and evolving topic to better support informed, evidence-based care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTGeoff Wall, PharmD, FCCP, BCPSProfessor of Pharmacy PracticeIowa Methodist Medical CenterRachel Maynard and Geoff Wall have no relevant financial relationships to disclose.Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current clinical evidence related to the use of leucovorin in autism and cerebral folate deficiency.2. Identify key counseling considerations for pharmacists discussing leucovorin therapy with patients and caregivers.0.05 CEU/0.5 HrUAN: 0107-0000-25-363-H01-PInitial release date: 12/1/2025Expiration date: 12/1/2026Additional CPE details can be found here.

Recent FDA actions have brought renewed attention to leucovorin as a potential treatment for managing symptoms associated with autism spectrum disorder. This course explores the clinical distinctions between autism and cerebral folate deficiency, reviews key evidence behind leucovorin use, and outlines counseling considerations relevant to pharmacy practice. You will gain clarity on this complex and evolving topic to better support informed, evidence-based care. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTGeoff Wall, PharmD, FCCP, BCPSProfessor of Pharmacy PracticeIowa Methodist Medical CenterRachel Maynard and Geoff Wall have no relevant financial relationships to disclose.  CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current clinical evidence related to the use of leucovorin in autism and cerebral folate deficiency.2. Identify key counseling considerations for pharmacists discussing leucovorin therapy with patients and caregivers.0.05 CEU/0.5 HrUAN: 0107-0000-25-363-H01-PInitial release date: 12/1/2025Expiration date: 12/1/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Listen in as our expert panel discusses critical aspects of managing patients on oral cancer therapies. Our experts review tips for optimizing patient care and share best practices for handling these specialized medications.Special guests:Jill Cassaday, BPharm, PharmD, BCPS, BCOPClinical Pharmacist Specialist – Multiple MyelomaBanner MD Anderson Cancer CenterSamuel Snowaert, PharmD, BCOP, MBAClinical Oncology Pharmacist Pharmacists Optimizing Oncology Care Excellence in Michigan (POEM)Covenant Cancer Care CenterLisa Thompson, PharmD, BCOP, CPPSClinical Pharmacy Specialist in Oncology Kaiser Permanente ColoradoYou'll also hear practical advice from TRC's Editorial Advisory Board member:Craig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in October 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter, or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: FAQ: Specialty MedsChart: Guide for Helping Patients Afford Their MedicationsChart: Drug Interactions: Cytochrome P450 (CYP), P-glycoprotein, and MoreToolbox: Medication Adherence StrategiesAlgorithm: Redosing Oral Medications After VomitingUse code mt1025 at checkout for 10% off a new or upgraded subscription.Send us a textEmail us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. Learn more about our product offerings at trchealthcare.com.

"Antibody–drug conjugates (ADCs) have three basic parts: the antibody part, the cytotoxic chemo, and the linker that connects the two. First, the antibody part binds to the target on the surface of the cell. Antibodies can be designed to bind to proteins with a very high level of specificity. That's what gives it the targeted portion. Then the whole thing gets taken up by the cell and broken down, which releases the chemotherapy part. Some sources will call this the 'payload' or the 'warhead.'  That's the part that's attached to the 'heat-seeking' part, and that's what causes the cell death," Kenneth Tham, PharmD, BCOP, clinical pharmacist in general oncology at the University of Washington Medicine and Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about antibody–drug conjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 28, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the mechanism of action of antibody–drug conjugates. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Antibody–Drug Conjugates Join the Best of Two Worlds Into One New Treatment Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer Oncology Nurses' Role in Translating Biomarker Testing Results The Pharmacist's Role in Combination Cancer Treatments ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin Fam-trastuzumab deruxtecan-nxki ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Other ONS resources: Antineoplastic Administration Huddle Card Biomarker Database Chemotherapy Huddle Card Monoclonal Antibodies Huddle Card Association of Cancer Care Centers (ACCC) antibody–drug conjugates page Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) National Cancer Institute cancer drugs page Network for Collaborative Oncology Development and Advancement (NCODA) clinical resource library ACCC/HOPA/NCODA/ONS Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The mechanism of action of the chemo itself depends on what agent or what 'warhead' is attached. Generally, [ADCs] have some kind of cytotoxic mechanism related to many of the chemotherapies that we use in practice, without attachment to the antibody. Some of them can be microtubule inhibitors, vinca alkaloids like vincristine. Some of them can be topoisomerase I (TOP1) inhibitors like irinotecan. Some can be alkylating agents that cause DNA breaks. So, again, looking back at the arsenal we have of cytotoxic chemo, these can all be incorporated into the ADCs." TS 5:54 "I want to talk about a case where the biomarker is being tested, but the biomarker isn't the target that you're looking for. One good case of this is a newer agent that was approved called datopotamab deruxtecan. The datopotamab portion is specific to a target called 'trophoblast cell surface antigen 2' (TROP2), which is expressed on the surface of many epithelial cancers. This agent was first approved in hormone receptor-positive, HER2-negative breast cancer, and received accelerated approval in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation. ... The antibody looks for a target, TROP2. But in both of these cases—in the breast cancer and the NSCLC—you're testing for expression of different mutations or lack thereof. You're not looking for expression of TROP2. There's more research that needs to be done about the relationship between TROP2 expression and the presence or absence of these other biomarkers, but until we know more, we're actually testing for biomarkers that aren't the target of the ADC." TS 10:22 "There are common adverse advents to antibodies and chemo in general. Because we have both of these components, we want to watch out for the adverse effects of both of them. Antibodies, as with most proteins, can trigger an immune response or an infusion reaction. So, many ADCs can also cause hypersensitivity or infusion reactions. The rates of that are really variable and depend on the actual antibodies themselves. Then you have the cytotoxic component, the chemotherapy component, which has its own characteristic side effects. So, if we think of general chemo side effects—fatigue, nausea, bone marrow suppression, alopecia—these can [occur] with a lot of ADCs as well." TS 15:34 "The rate of ocular toxicity in [mirvetuximab soravtansine] is quite high. The manufacturer reports that this can occur in up to 60% of patients. With rates so high, the manufacturer recommends a preventive strategy. For this particular agent, [they] recommend patients have required eyecare. ... This ocular toxicity is something we do see in other ADCs that don't have the same target and don't necessarily have the same payload component. For example, tisotumab vedotin and again, datopotamab deruxtecan, can both cause ocular toxicities and both would have required ocular supportive care." TS 20:08 "Overall, I feel like the future is incredibly bright for these agents. There have only been around a dozen therapies approved by the U.S. Food and Drug Administration (FDA) despite this idea—the first agent came out in 2000. So, 25 years later, there are only around a dozen FDA-approved treatments. But there are so many more that are coming through the pipeline. And as we're discovering more biomarkers and developing more specialized antibodies, it's only natural that more ADCs will follow." TS 26:50

ABOUT THIS EPISODE Who is a pharmacist, and how are they involved in the care of neuroendocrine cancer patients? In this episode, Dr. Amanda Cass, a clinical pharmacist in the Thoracic Oncology Clinic at Vanderbilt Medical Center, explains the unique role pharmacists play—why they're sometimes called “doctor,” how they support patients starting treatments such as cabozantinib and CAPTEM, and practical tips for staying organized, managing side effects, and navigating medication costs. TOP TEN QUESTIONS Getting to Know the Pharmacist1. What exactly does a pharmacist do, and what training do they go through?2. Why are pharmacists sometimes called “doctor,” and how is that different from a physician? 3. What role does a pharmacist play on the cancer care team? 4. How are pharmacists involved in caring for neuroendocrine cancer patients, both directly and behind the scenes?How Pharmacists Support Treatment5. How can a pharmacist help when someone is starting a new treatment for neuroendocrine cancer? Walk us through an example with Cabozantinib: how do you guide patients in understanding it, taking it, and managing side effects?6. Walk us through another example with CAPTEM (capecitabine and temozolomide): how do you guide patients in understanding it, taking it, and managing side effects?Practical Tips for Patients7. What are some simple ways to stay organized, like keeping a medication list or symptom journal? 8. What practical tips do you share with patients about tracking and managing side effects at home?Access and Communication9. Who can patients talk to about medication costs or financial assistance?10. How does someone find a pharmacist to talk to, and is it important to find one with neuroendocrine cancer experience?ABOUT AMANDA CASSDr. Cass is a clinical pharmacist in the Thoracic Oncology Clinic at Vanderbilt University Medical Center. She received her Doctorate of Pharmacy from the University of Kentucky College of Pharmacy in 2016 and subsequently completed her Pharmacy Practice Residency at Grady Health System and became a Board Certified Pharmacotherapy Specialist in 2017. In 2018, she completed her Oncology Pharmacy Residency at the University of North Carolina Medical Center.Dr. Cass's previous research interests included opioid use in non-metastatic cancer patients after curative treatment and albumin effects on oxaliplatin related toxicities. Her current areas of interest are molecular mutations and use of targeted therapies in NSCLC, immunotherapy in SCLC, and global oncology care.Dr. Cass is the preceptor for the Outpatient Thoracic Oncology Rotation.For more information, visit NCF.net/podcast/50For more information, visit NCF.net.

Send us a textSchedule an Rx AssessmentSubscribe to Master The MarginWhat does it really take to start and sustain a successful compounding pharmacy in 2026? In this episode, Scotty Sykes, CPA, CFP®, and Austin Murray sit down with Amy Summers, PharmD, BCSCP and of Restore Health Consulting, to discuss how pharmacy owners can move from idea to implementation when entering the compounding space.We cover:Designing a purpose-built facility for USP standards and your product mixThe mindset shift from dispensing to creating and how to balance quality with patient careMarket analysis, relationships, and niche focus in building a sustainable businessKey trends driving growth, consolidation, and private investment in the compounding industryMore About Our Guest:Amy Summers, PharmD, BCSCP is an independent consultant, specializing in business, operations, quality assurance, and regulatory compliance matters for the pharmaceutical compounding industry. She earned her PharmD degree from the University of California San Francisco and was among the first pharmacists in the nation to earn a Board Certified Sterile Compounding Pharmacist (BCSCP) credential. Dr. Summers has spent her entire career as a pharmacist in various settings centered around non-sterile and sterile compounding. She has formerly served as Director of Operations and Pharmacist in Charge at organizations engaged in compounding and also as Managing Director of a FDA-registered 503B outsourcing facility. With extensive experience in USP standards, accreditation, cGMP, and regulatory compliance, Dr. Summers has also served as an expert witness for matters related to compounding.Stay connected with Amy and Restore Health Consulting: Amy Summers LinkedInRestore Health Consulting WebsiteRestore Health Consulting LinkedInStay connected with us on social media:Facebook: https://www.facebook.com/sykesandcoTwitter: https://twitter.com/OllinSykesLinkedIn: https://www.linkedin.com/company/sykes-&-company-p-a-?trk=tyahScotty Sykes – CPA, CFP® LinkedIn: https://www.linkedin.com/in/scottysykes/More on this topic:Podcast: The Trusted Pharmacist: Advocacy and Building a Resilient PharmacyPodcast: From Counter to Capitol

Listen in as experts Thomas P. Lodise, PharmD, PhD, and George Sakoulas, MD, FIDSA, explore tailored antibiotic strategies for diverse patients with acute bacterial skin and skin structure infections (ABSSSIs). Their insightful discussion focuses on antibiotic developments that followed publication of the IDSA practice guidelines in 2014 and the challenges unique to ABSSSIs, including a lack of determined bacterial etiology for many cases. PresentersThomas P. Lodise, PharmD, PhDProfessorAlbany College of Pharmacy and Health SciencesInfectious Diseases Clinical Pharmacy SpecialistStratton VA Medical CenterAlbany, New YorkGeorge Sakoulas, MD, FIDSAChief, Infectious DiseasesSharp Rees-Stealy Medical GroupAdjunct Professor of PediatricsUniversity of California San Diego School of MedicineSan Diego, CaliforniaLink to full program:https://bit.ly/4oIKwzsGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On this episode of The Vitamin Professor Podcast, Professor Gene Bruno talks to Meagan Garza, PharmD of BOIRON, USA.This podcast is brought to you in partnership with VRM Media and Nutraland USA, Inc.For more information about our host and guest, please see the below information.boironusa.comhttps://www.linkedin.com/in/meagan-garza-pharmd-747a39189/nutralandusa.comlinkedin.com/in/gene-bruno-ms-mhs-rh-ahg-2ab0508/www.vrmmedia.com@hnvirtual, #hnvirtual, #meagangarza, #genebruno, #thevitaminprofessorFind our podcast on your favorite platform:podcasts.apple.com/us/podcast/the-vitamin-professor-podcast/id1746137375youtube.com/channel/UCxeQ-IuqCRmq0YLc7jQNMKAmusic.amazon.com/podcasts/a8a96593-b93c-48cf-9fe9-2891c4035dad/the-vitamin-professor-podcastiheart.com/podcast/269-the-vitamin-professor-podc-175888136/

Another powerful episode is live here on IVPN-Voice!

Catie Stimmel, PharmD, joined Over the Counter to discuss the importance of patient safety organizations for the greater health care continuum.

If you're wondering which therapies may influence care delivery, budgets, and decision making in 2026, the pipeline offers an early preview and it points to a year defined by innovation. We're seeing new first in class treatments, thoughtful next generation agents, and a biosimilar market where fewer launches are offset by important competitive shifts driven by recent approvals. John Schoen and Heather Pace from the Center for Pharmacy Practice Excellence join Stacy Lauderdale, Associate Vice President of Evidence-Based Medicine and Drug Information and your Verified RX program host to highlight pipeline agents worth watching and discuss what they may mean for care delivery and spend management in the year ahead.   Guest speakers:  John Schoen, PharmD, BCPS   Senior Clinical Manager of Drug Information    Vizient Center for Pharmacy Practice Excellence    Heather Pace, PharmD Senior Clinical Manager of Drug Information    Vizient Center for Pharmacy Practice Excellence      Host:   Stacy Lauderdale, PharmD, BCPS   Associate Vice President  Vizient Center for Pharmacy Practice Excellence   Show Notes: 01:01 — Episode Scope The focus is non-CGT therapies; CGT pipeline will be covered in Part 2. 01:50 — Therapeutic Areas With the Most Approvals Oncology leads the pipeline. Others include infectious disease, neurology, rare disease, endocrine, hepatology, dermatology, and rheumatology. 02:37 — Biosimilars in 2026: Momentum or Headwinds? Discussion of potential “biosimilar void”—only 10% of expiring biologic patents have biosimilars in development. Emerging role of PBM private-label biosimilars. 03:51 — FDA Draft Guidance on Interchangeability FDA exploring interchangeable designation for all biosimilars. Potential shift away from clinical efficacy studies in favor of analytical comparisons. Guidance still in draft and open for public comment. 05:34 — John's Top Picks for First-in-Class Agents 06:11 — Orviglance First manganese-based, oral MRI contrast agent. Advantages for patients with kidney impairment. Used for liver imaging. 06:20 — Why Non-Gadolinium Matters Lower risk of nephrogenic systemic fibrosis. 06:46 — Tabelecleucel First allogeneic EBV-specific T-cell therapy. For EBV-positive PTLD post-transplant. Could become new standard of care. 07:42 — Tanruprubart First therapy specifically for severe Guillain-Barré Syndrome (GBS). Shows improved outcomes over IVIG and plasma exchange. 08:20 — Comparing to Standard of Care Review of improved real-world data outcomes. 09:03 — Therapies That May Shift Care Delivery 09:32 — Icotrokinra: First oral IL-23 antagonist for plaque psoriasis. 10:00 — Insulin Icodec First once-weekly basal insulin for type 2 diabetes. Resubmitted after safety concerns in type 1 diabetes. 10:59 — Honorable Mentions Camizestrant SERD for ER+/HER2– metastatic breast cancer. Ensitrelvir (COVID-19) Oral option for pre-exposure prophylaxis. Also being evaluated for treatment. Doravirine + Islatravir (HIV) Introduces new NRTTI class. Cefepime + Zidebactam Active against metallo-β-lactamase–producing organisms. 14:05 — Key Biosimilar Launches Omalizumab (Xolair) First biosimilars in asthma/allergy space. Aflibercept (Eylea) High competition expected pending litigation. Pertuzumab (Perjeta) First biosimilar anticipated in oncology. 15:31 — Biosimilars Approved in 2025, Impacting 2026 Ustekinumab (Stelara): first full year of competition Denosumab (Prolia/Xgeva): 10–15 biosimilars expected Eculizumab (Soliris): notable for rare disease market entry 17:17 — John's Closing Thoughts Strong mix of first-in-class advances and next-gen convenience therapies. 17:36 — Heather's Closing Thoughts 2026 will focus on speed and scale after the 2025 biosimilar wave. Pharmacists pivotal in ensuring smooth patient transitions.   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Today we are bringing you a conversation on the evolving landscape for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) treatment. Ryan Haumschild, PharmD, MS, MBA, vice president of ambulatory pharmacy at Emory Healthcare and Winship Cancer Institute, spoke with Marilyn Glassberg, MD, the John W. Clarke Professor and Chair of medicine at Loyola University Chicago Stritch School of Medicine; Ayodeji Adegunsoye, MD, MSc, PhD, FACP, FCCP, assistant professor at the University of Chicago; and Janet Pope, MD, MPH, professor of medicine and division member of rheumatology at the University of Western Ontario in Canada. IPF and PPF are increasingly prevalent conditions that pose a growing burden on both patients and health care systems. Despite the availability of FDA-approved antifibrotic therapies, the median survival for patients with IPF and PPF remains less than 5 years after diagnosis—underscoring the critical unmet needs that persist in this field. The panelists discussed the impact these conditions have on patients' lives, evaluated emerging agents, and addressed economic considerations that affect treatment decisions and health care resource allocation.

Join Ryan K. Shields, PharmD, MS, in the second of three recap podcasts taken from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients.” Learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include:The diverse mechanisms of β-lactam resistanceThe effect of resistance mechanisms on susceptibility to antimicrobials 2024 IDSA guidance for treatmentConsiderations for antibiotic selectionThe role of combination therapyPresenter:Ryan K. Shields, PharmD, MS Associate Professor of MedicineCo-Director, Center for Innovative Antimicrobial TherapyUniversity of PittsburghCo-Director, Antibiotic Management ProgramUPMC Presbyterian HospitalPittsburgh, PennsylvaniaLink to full program and downloadable slides:CCO: https://bit.ly/3LXzateProCE: https://bit.ly/3Mjao6GGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Ryan K. Shields, PharmD, MS, in the third of 3 podcasts from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients” to learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include:Mechanisms of resistance in S. maltophiliaCurrent frontline therapies2024 IDSA guidance for treatmentPresenter:Ryan K. Shields, PharmD, MS Associate Professor of MedicineCo-Director, Center for Innovative Antimicrobial TherapyUniversity of PittsburghCo-Director, Antibiotic Management ProgramUPMC Presbyterian HospitalPittsburgh, PennsylvaniaLink to full program and downloadable slides:https://bit.ly/3JWaqRvGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Society of Critical Care Medicine (SCCM) Podcast, host Marilyn Bulloch, PharmD, BCPS, FCCM, speaks with Terry Fulmer, PhD, RN, FAAN, President of the John A. Hartford Foundation, about her Norma J. Shoemaker Honorary Lecture at the 2025 Critical Care Congress and the transformative impact of the 4Ms framework—What Matters, Medication, Mentation, and Mobility—on age-friendly critical care. Dr. Fulmer shares her journey from bedside critical care nurse to national leader in geriatric health, emphasizing the need to adapt healthcare systems to meet the needs of an aging population. She discusses the development of the Age-Friendly Health Systems initiative, a collaboration among the John A. Hartford Foundation, Institute for Healthcare Improvement, American Hospital Association, and Catholic Health Association. Now implemented in nearly 5000 facilities, the initiative is supported by evidence from models such as the Acute Care of the Elderly (ACE) units, Hospital Outcomes Program for Elders (HOPE) initiative, and Nurses Improving Care for Healthsystem Elders (NICHE) program. The episode highlights the January 2025 adoption of a Centers for Medicare and Medicaid Services measure that incorporates the 4Ms into inpatient care standards. Dr. Fulmer explains how hospitals of all sizes can implement age-friendly practices using existing resources and how multiprofessional collaboration is key to success. She also discusses findings from a national survey from Age Wave and the John A. Hartford Foundation, which revealed that only 19% of older adults feel their clinicians consistently address all 4Ms. Listeners will gain insight into how the 4Ms framework improves outcomes and promotes functional recovery in older adults. Whether you're a clinician, educator, or healthcare leader, this episode offers practical strategies and a compelling call to action to join the age-friendly health systems movement.

Pharmacists play a critical role in infectious disease care, and staying up to date on antibiotic therapies is key to ensuring optimal patient outcomes. This episode reviews recently FDA-approved antibiotics, offers a practical refresher on commonly used antibiotic classes, and highlights frequent side effects—along with strategies for managing them in practice. Tune in to strengthen your clinical knowledge and support safe, effective antibiotic use across care settings.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTHunter Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship CoordinatorSSM HealthJoshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.  Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify newly FDA-approved antibiotics and their clinical indications.2. Describe commonly used antibiotic classes, their typical side effects, and strategies to manage or mitigate those effects.0.05 CEU/0.5 HrUAN: 0107-0000-25-362-H01-PInitial release date: 11/24/2025Expiration date: 11/24/2026Additional CPE details can be found here.

Pharmacists play a critical role in infectious disease care, and staying up to date on antibiotic therapies is key to ensuring optimal patient outcomes. This episode reviews recently FDA-approved antibiotics, offers a practical refresher on commonly used antibiotic classes, and highlights frequent side effects—along with strategies for managing them in practice. Tune in to strengthen your clinical knowledge and support safe, effective antibiotic use across care settings. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTHunter Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship CoordinatorSSM HealthJoshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.   CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify newly FDA-approved antibiotics and their clinical indications.2. Describe commonly used antibiotic classes, their typical side effects, and strategies to manage or mitigate those effects.0.05 CEU/0.5 HrUAN: 0107-0000-25-362-H01-PInitial release date: 11/24/2025Expiration date: 11/24/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Send us a textIn our latest episode of the Joint Dynamics podcast host Andrew Cox | Joint Dynamics chats with Robert R Beltran MD, Pharm D, Triple Board Certified Surge and Founder of Recomnd Nutrition, a pioneering wellness brand focused on scientifically backed herbal supplements. Dr. Beltran shares his remarkable transition from a distinguished career in plastic and facial reconstructive surgery to entrepreneurship, sparked by a life-altering injury and a subsequent challenging battle with pain relief medication addiction spanning over 2 years. He discusses the dangers of extended medication use, his philosophy on holistic health, and the transformative power of traditional herbal medicine in recovery, performance and wellness.Join this inspiring conversation on healing, innovation, and exploring health beyond pharmaceuticals.Show sponsor is Muvitality Medicinal Mushrooms for modern day health and wellness | Mu …Go to muvitality.com and use the code JD10 to receive a 10% discount on your purchase of Mu Functional mushrooms such as Lions Mane, Cordyceps, Chaga, Reishi, and Turkey tail functional mushroomsHere are some useful links for this podcastrecomnd.comInstagram: https://www.instagram.com/recomnd.nutrition/LinkedIn: https://www.linkedin.com/in/robert-r-beltran-md/Relevant episodesEpisode 120 - YOUR MORNING ERECTIONS LINK TO HEART DISEASE with Men's health specialist Colin Symmonds - https://podcasts.apple.com/hk/podcast/episode-120-your-morning-erections-link-to-heart-disease/id1527374894?i=1000692986665JOINT DYNAMICS links:Joint Dynamics Facebook - https://www.facebook.com/JointDynamicsHongKong/Joint Dynamics Instagram -https://www.instagram.com/jointdynamics/Joint Dynamics Youtube - https://www.youtube.com/channel/UCRQZplKxZMSvtc6LxM5WckwJoint Dynamics Website - www.jointdynamics.com.hk Host - Andrew Cox - https://www.jointdynamics.com.hk/the-team/trainers/andrew-cox

Special Guest: Ilisa B.G. Bernstein, PharmD, JD CEO & Co-founder Johny Kello | MatchRX Topic: DSCSA Compliance, Industry Readiness & the Future of Pharmacy Safety Episode Overview This week on TWIRx, Johny Kello welcomes one of the 50 Most Influential People in Pharmacy, Ilisa B.G. Bernstein, PharmD, JD, to break down the current state of DSCSA compliance as the industry approaches the critical November 2025 enforcement deadline. With decades of leadership in pharmacy practice, regulatory policy, and national advocacy, Dr. Bernstein brings unmatched clarity to what pharmacies must do now — and how the right technology partnerships can keep them operational, efficient, and fully compliant. Together, Johny and Dr. Bernstein discuss why DSCSA readiness remains one of the most pressing challenges for independent and community pharmacies — from data verification and product tracing to avoiding shipment rejections, workflow disruptions, and audit exposure. Johny Kello LinkedIn: https://www.linkedin.com/in/johny-kello/   Ilisa B.G. Bernstein, PharmD, JD LinkedIn: https://www.linkedin.com/in/ilisa-bernstein-b67222174/ Learn more: https://www.matchrx.com/ Featured guest: Dr. Jordyn Nordé, PharmD, MBA, is a forward-thinking clinical pharmacist and community leader based in St. Louis who combines advanced clinical training with business acumen to drive impact in underserved populations. With experience in ambulatory care and medication management for conditions like hypertension, diabetes and pain, she is also the founder of an initiative bringing minority pharmacy professionals together through mentorship, entrepreneurship and wellness conversations. Her dual credentials enable her to bridge healthcare, professional development and advocacy — positioning her as an emerging influencer in pharmacy practice transformation. LinkedIn: https://www.linkedin.com/in/jordynnorde/

In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Matthew G. Bowles, PharmD, MBA, CSP, Pharmacy Clinical Team Lead with Vanderbilt Specialty Pharmacy, Vanderbilt Health, and lead author on the study “Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey,” published February 2025 in the Journal of Managed Care & Specialty Pharmacy. They discuss the reasons for conducting and results of the study, as well as the impacts the study may have on specialty and managed care pharmacy.

Hi and welcome to How Humans Heal. I'm Dr. Doni Wilson, and in today's episode I'm talking with Dr. Nayan Patel. He's a PharmD (a pharmacist) and owns two compounding pharmacies. Dr. Patel is also the author of "The Glutathione Revolution: Fight Disease, Slow Aging, and Increase Energy." He does incredible work in product development and research at Auro Wellness, and he's here to share that knowledge with us. As a pharmacist, Dr. Patel has a wealth of wisdom and decades of experience. Dr. Patel has been a pharmacist for about eight years now, and before that he worked in a compounding pharmacy since 1993. Dr. Patel's interest in glutathione started from working in a compounding pharmacy where glutathione was the solution for many patients. Glutathione is that thing that takes work away from your body. It's an antioxidant. It's a massive detoxifier. It helps the liver detoxify chemicals. Once you do that, the body frees up, and when it frees up, it starts healing, rejuvenating, regenerating. It's a multitasker, a multi-tool antioxidant. Even applying glutathione on your arms, it circulates around your whole body and eventually gets to all your cells. I love this conversation with Dr. Patel because he's found a way to support our bodies to recover from stress and toxin exposure using glutathione, our most powerful antioxidant. So check out today's conversation! We're here to help you! LINKS FROM THE EPISODE:   Connect with Dr. Patel: https://aurowellness.com/doctordoni    Sign Up For Your 14-Day Detox: https://doctordoni.com/detox-program   Schedule A Chat With Dr. Doni: https://intakeq.com/new/hhsnib/vuaovx    Read the full episode notes and find more information: https://doctordoni.com/blog/podcasts/ MORE RESOURCES FROM DR. DONI:   Quick links to social media, free guides and programs, and more: https://doctordoni.com/links     Disclosure: Some of the links in this post are product links and affiliate links and if you go through them to make a purchase I will earn a commission at no cost to you. Keep in mind that I link these companies and their products because of their quality and not because of the commission I receive from your purchases. The decision is yours, and whether or not you decide to buy something is completely up to you.

This is the 13th episode in my Pharmacist Podcasters Series. My guests and I talk about podcasting to inspire you to start your own podcast, be a podcast guest, or use your voice in general. If you're interested in podcasting, pod-guesting or public speaking, you need to listen to this episode (and the Series!). My guest today is Dr. Brooke Griffin, host of the 5 Minute Pep Talk Podcast. If you need a short, motivational podcast with a positive vibe that gets to the point quickly, subscribe to or follow The 5 Minute Pep Talk today.    Click to read the FULL show notes: https://www.thepharmacistsvoice.com/podcast (select episode 357)   Background information for Brooke Griffin, PharmD (October 2025)   Brooke Griffin, PharmD, BCACP is a Professor of Pharmacy Practice and Vice Chair of Clinical Services at Midwestern University College of Pharmacy. She is a Professional Coach in Life & Work and is passionate about offering career support through a thought-provoking and creative process.  In 2022 she launched Bold Idea Group with a mission to inspire bold ideas from within. She loves providing a positive space in our profession while acknowledging that it's a roller coaster of excitement and stress. For coaching tools, inspiration, and to learn more about Brooke, listen to her 5-minute podcast, "5 Minute Pep Talk." She is on this self-development journey alongside all of you and believes "every pharmacist deserves a coach."   Share this episode! If you know someone who might like this episode, please share this episode with them. Subscribe to or follow The Pharmacist's Voice ® Podcast on your favorite podcast player and YouTube to get each new episode when it comes out. Popular links are below.   Apple Podcasts   https://apple.co/42yqXOG  Spotify  https://spoti.fi/3qAk3uY  Amazon/Audible  https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt   If you need help starting your podcast, I can help. I coach students one-on-one, sell a self-paced online course, and sell a book about podcast planning. Get my book in print, eBook, or audiobook on amazon.com. You can also listen to the episodes about podcasting in my back catalog on thepharmacistsvoice.com/podcast.    Links from this episode  Follow the 5 Minute Pep Talk on your favorite podcast player https://rss.com/podcasts/todaysboldidea/?listen-on=true  5 Minute Pep Talk on Apple Podcasts https://podcasts.apple.com/us/podcast/5-minute-pep-talk-mindset-motivation-and-coaching-for/id1757538544  5 Minute Pep Talk on Spotify https://open.spotify.com/show/6CSKzhnuhQWy2HyImxN2fD Brooke on LinkedIn https://www.linkedin.com/in/brookegriffinpharmd/  Brooke's Free Private Facebook Group https://www.facebook.com/groups/boldideagroup  Brooke's Business Website https://www.boldideagroup.com/  Big Magic: Creative Living Beyond Fear by Elizabeth Gilbert KNOWN: The Handbook for Building and Unleashing Your Personal Brand in the Digital Age by Mark W. Schaefer Building a StoryBrand: Clarify Your Message So Customers Will Listen by Donald Miller  Pharmacist Podcaster: A Podcast Planning Guide for Pharmacy Professionals by Kim Newlove   Pharmacist Podcasters Series Part 1 with Ola Latala, PharmD (The Pharmacist's Voice Podcast Episode 248) Part 2 with Deeb Eid, PharmD (The Pharmacist's Voice Podcast Episode 253) Part 3 with Justin Cole, PharmD (The Pharmacist's Voice Podcast Episode 257) Part 4 with Christina Fontana, PharmD The Pharmacist's Voice Podcast Episode 262 Part 5 with Tony Dao, PharmD The Pharmacist's Voice Podcast Episode 266 Part 6 with Dr. H (Hussam Hamoush, PharmD) The Pharmacist's Voice Podcast Episode 275 Part 7 with Julie Doan, PharmD The Pharmacist's Voice Podcast Episode 297 Part 8 with Tim Ulbrich, PharmD The Pharmacist's Voice Podcast Episode 306  Part 9 with Zain Syed, PharmD The Pharmacist's Voice Podcast Episode 310 Part 10 with Rachel Gainsbrugh, PharmD The Pharmacist's Voice Podcast Episode 323  Part 11 with Danielle Plummer, PharmD The Pharmacist's Voice Podcast Episode 329 Part 12 with Cory Jenks, PharmD The Pharmacist's Voice Podcast Episode 334    Kim's websites and social media links: ✅ Guest Application Form (The Pharmacist's Voice Podcast) https://bit.ly/41iGogX  ✅ Monthly email newsletter sign-up link https://bit.ly/3AHJIaF  ✅ LinkedIn Newsletter https://bit.ly/40VmV5B ✅ Business website https://www.thepharmacistsvoice.com ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ Pronounce Drug Names Like a Pro © Online Course https://www.kimnewlove.com  ✅ Pharmacist Podcaster Book https://amzn.to/4iAKNBs  ✅ Podcasting Online Course https://www.kimnewlove.com/podcasting  ✅ Private Podcasting Coaching or Consulting https://www.kimnewlove.com/private-coaching  ✅ LinkedIn https://www.linkedin.com/in/kimnewlove ✅ Facebook https://www.facebook.com/kim.newlove.96 ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with the same coach who helped me get started (Dave Jackson from The School of Podcasting)! **Affiliate Link - NEW 9-8-23**      Thank you for listening to episode 357 of The Pharmacist's Voice ® Podcast.  If you know someone who would like this episode, please share it with them!

Joining Robert Pilot: Heather Maracle Fahey, PharmD

On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV.  Subcutaneous lenacapavir is administered twice a year (every six months) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at risk. With patients only needing lenacapavir twice a year for HIV prevention, the field has been optimistic about the potential for lenacapavir to reduce barriers and improve access to PrEP. Since we are still early in the rollout subcutaneous lenacapavir, many providers have questions about how to offer it to their patients—from workflow to billing to managing potential side effects and drug-drug interactions. On this episode, Antonio Urbina, MD, Medical Director for CEI's HIV Primary Care and Prevention Center of Excellence, speaks with Alex Danforth, PharmD. Alex Danforth is a clinical pharmacist in Rochester, NY.  She practices at Trillium Health, a federally qualified health center, where she works with patients and providers to help manage medications and optimize care.  Alex currently provides clinical leadership for HIV treatment and prevention programs.  Drs. Urbina and Danforth talk about the latest New York State Clinical Guidelines for PrEP, which were updated on October 16th. The new guidelines provide important updates, including subcutaneous lenacapavir. They discuss important considerations for initiating patients on lenacapavir as well as some early lessons learned from implementing lenacapavir in their Rochester- and New York City-based clinics. Related Content:  PrEP to Prevent HIV and Promote Sexual Health University of Liverpool HIV Drug Interactions Checker (website and app) CEI Line: 1-866-637-2342 https://ceitraining.org/

This episode includes extended Q&A sessions that address your unanswered questions from the following presentations delivered at the 2025 Fall Congress in Colorado Springs, Colorado:  (00:22) A Discussion of Substance: Supporting Meaningful Improvements in the Lives of Patients Struggling With Substance Use Disorders by Brittany Albright, MD and Hara Oyedeji, DNP, PMHNP-BC (Q&A with Dr. Albright)  (34:08) Nightmares and Brainscapes: Emerging Therapeutic Avenues in the Treatment of PTSD by Lori Davis, MD and Andrew Cutler, MD (Q&A with Dr. Davis)  (47:43) Sex, Pudge, and Eyes That Close: Strategies to Address Common Psychotropic–Induced Tolerability Issues by Leslie Citrome, MD and Andrew Cutler, MD (Q&A with Dr. Citrome)   (55:00) When Less Is More: Strategies for Deprescribing Psychotropic Medications by Jeffrey Strawn, MD and Kari Franson, PharmD, PhD, BCPP (Q&A with Dr. Strawn)  Never miss an episode!

Struggling to fall asleep, or stay asleep? In this episode, pharmacist Bryana Gregory, PharmD, RPh, explains why sleep is a root-cause issue that drives hormone balance, immune strength, metabolism, and daily performance. She covers how circadian rhythm, light exposure, stress, pain, and life stages (like menopause) influence sleep quality, and why fixing daytime cues is just as important as what you take at night.   Bryana dives into melatonin beyond the basics: what melatonin is, why production declines with age, and how targeted formulations can match your sleep patterns. For trouble falling asleep, she discusses immediate-release sublingual tablets; for middle-of-the-night wakeups, sustained or delayed-release capsules; and how some guests benefit from both. She also addresses long-term use, safety, dosage personalization, and the value of potency-verified, compounded prescriptions free of common fillers. Learn more about melatonin and other practical tips for improving your sleep and overall health. Watch now and subscribe to our podcasts at www.HotzePodcast.com.   To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!  

In this episode of Diabetes Day by Day, Drs. Neil Skolnik and Sara Wettergreen talk with Dr. Akturk about the potential health risks associated with cannabis use for people living with diabetes. Cannabis use can affect blood glucose management, heart health, and even how someone manages their medications.  Understanding the risks of cannabis use is an important part of managing diabetes safely. Staying informed and having open conversations with your health care team are the best ways to protect your health. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Halis Kaan Akturk, MD, Associate Professor of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!

He was told to expect paralysis or death. Instead, he reclaimed his life. In this episode of Vitality Made Simple, Jason Barrett, PharmD  joins us to share his story through years of crippling pain and an autoimmune diagnosis that left him fearing paralysis or death. He explains how discovering hidden food sensitivities, changing his diet, addressing oral infections, and simplifying his lifestyle helped him reclaim his vitality and bring real hope to others stuck in the chronic illness spiral.Visit my website DrDebbieOzment.com for valuable free downloads. Additionally, you will find shopping links which I have curated on the website. Please follow me on instagram at drdebbieozment.

Rapid phenotypic antimicrobial susceptibility testing (AST) significantly reduces time to actionable results and can improve antibiotic decision-making for patients with bloodstream infections. Listen in to learn from Michael P. Veve, PharmD, MPH, how to optimally integrate rapid phenotypic AST into clinical practice, including incorporation into your existing antimicrobial stewardship workflow. Topics covered include:Considerations for implementationDecision-making steps for implementationThe role of antimicrobial stewardship programs in AST workflowPresenter:Michael P. Veve, PharmD, MPHClinical Associate ProfessorDepartment of Pharmacy PracticeEugene Applebaum College of Pharmacy and Health SciencesWayne State UniversityClinical Pharmacy Specialist, Infectious DiseaseHenry Ford HospitalDetroit, MichiganLink to full program and downloadable slides:https://bit.ly/4inoXCxGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Dr. Narjust Florez as she explores complementary and integrative medicine in lung cancer care with leading experts Dr. Ting Bao, Dr. Jun J. Mao, and Dr. Lisa Davis. This episode clarifies the differences between alternative, complementary, and integrative approaches while addressing oncologists' concerns about safety and drug interactions. Learn where to find reliable information, what the research shows about treatments like acupuncture and supplements, and how patients can safely incorporate these therapies into their cancer journey. Guests: Ting Bao, MD, MS, FSIO Co-Director, Leonard P. Zakim Center for Integrative Therapies and Healthy Living Member of the Faculty, Harvard Medical School Dana-Farber Cancer Institute Jun J. Mao, MD, MSCE Chief, Integrative Medicine Service Laurance S. Rockefeller Chair in Integrative Medicine Professor of Medicine, Weill Cornell Medicine Memorial Sloan Kettering Cancer Center Lisa Davis, PharmD, FCCP, BCPS, BCOP, Clinical Professor, Pharmacy Practice & Science The University of Arizona, R. Ken Coit College of Pharmacy

In this episode, Eric Huckins discusses trends shaping specialty pharmacy, from managing high-cost infusions and direct-to-consumer models to preparing for the Inflation Reduction Act. He shares how Lumicera is partnering with health systems to enhance efficiency, integration, and patient care.This episode is sponsored by Lumicera Health Services.

Gibran Ameer, PharmD, CEO of VirtueTechnologies, joins the WeInfuse podcast to unpack how pharmacy and infusion workflows connect in the real world. He shares his path into infusion, the biggest challenges he sees from the chair to the courier, and a behind-the-scenes story that shows why shipment visibility and proof of delivery matter. Gibran explains his light bulb moment about unifying data across portals and walks through the VirtueScript integration with WeInfuse, including how shipment details and proof of delivery flow back into WeInfuse in a normalized, audit-ready format. 

ASHP's senior education director, Cindy Von Heeringen is joined by William Dager, pharmacist specialist (Ret.) at University of California, Davis Medical Center, as he discusses his upcoming Midyear session that focuses on anticoagulation management plans in complex patients. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Discover the benefits of implementing a long-acting injectable (LAI) service at your pharmacy practice site and the impact this service can have on patient care and outcomes. Listen to this week's episode and learn how to elevate your pharmacy services! HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTLindsay McCoy, PharmD, BCPPPharmacy ManagerVillage Drug Shop at AdvantagePharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Analyze the benefits and challenges of implementing a long-acting injectable (LAI) service in a pharmacy practice site.2. Discuss how an LAI service can improve patient care, increase financial sustainability, and optimize patient outcomes.0.05 CEU/0.5 HrUAN: 0107-0000-25-354-H01-PInitial release date: 11/17/2025Expiration date: 11/17/2026Additional CPE details can be found here.Take your pharmacy practice to the next level with our comprehensive course on the administration of long-acting injectables:Pharmacy-Based Administration of Long-Acting Injectables: A Sharp Idea4 hours  |  On DemandExplore a cutting edge clinical service opportunity with this collection of courses specifically designed to equip pharmacists with the knowledge and skills necessary for the effective management and administration of long-acting injectable medications (LAIs). Course content explores diverse drug profiles, advanced administration techniques, and the strategic implementation of LAI-related services to support the needs of your patients and communities.

Discover the benefits of implementing a long-acting injectable (LAI) service at your pharmacy practice site and the impact this service can have on patient care and outcomes. Listen to this week's episode and learn how to elevate your pharmacy services! HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTLindsay McCoy, PharmD, BCPPPharmacy ManagerVillage Drug Shop at AdvantageCPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Analyze the benefits and challenges of implementing a long-acting injectable (LAI) service in a pharmacy practice site.2. Discuss how an LAI service can improve patient care, increase financial sustainability, and optimize patient outcomes.0.05 CEU/0.5 HrUAN: 0107-0000-25-354-H01-PInitial release date: 11/17/2025Expiration date: 11/17/2026Additional CPE details can be found here.Take your pharmacy practice to the next level with our comprehensive course on the administration of long-acting injectables:Pharmacy-Based Administration of Long-Acting Injectables: A Sharp Idea4 hours  |  On DemandExplore a cutting edge clinical service opportunity with this collection of courses specifically designed to equip pharmacists with the knowledge and skills necessary for the effective management and administration of long-acting injectable medications (LAIs). Course content explores diverse drug profiles, advanced administration techniques, and the strategic implementation of LAI-related services to support the needs of your patients and communities.Follow CEimpact on Social Media:LinkedInInstagram

As more people depend on them for local, personalized care, a new report from CVS Health sheds some light on what's ahead. Tune in for Lucille Accetta, Chief Pharmacy Officer, and Pharmacy Manager Edwin McGee from CVS Health.Moments with Marianne airs in the Southern California area on KMET 1490AM & 98.1 FM, an ABC Talk News Radio Affiliate!  https://www.kmet1490am.com  Lucille Accetta is Chief Pharmacy Officer, CVS Health, who advocates to elevate the practice of pharmacy in health care as key to improving health outcomes and lowering the cost of care. She is responsible for creating and implementing strategic opportunities to connect CVS Health pharmacy assets across the enterprise. As Senior Vice President and Head of CVS Specialty Operations, Lucille leads CVS Health's specialty pharmacies which support more than 1.8 million patients.   Dr. Edwin McGee is a District Leader Emerging Leader (DLEL) for CVS Pharmacy, based in Huntsville, AL. His journey began as a pharmacy technician, where he steadily took on roles of increased responsibility, demonstrating his pharmacy care expertise and strong leadership qualities. Edwin is currently managing a high-performing and successful pharmacy team and continues to exhibit his leadership while serving his local community. Recently, he was awarded a 2024-2025 CVS Health National Paragon Award, recognizing his contributions and impact amongst his peers and his patients. cvshsealth.com/rx-reportFor more show information visit: www.MariannePestana.com

>>Join our FREE monthly Gut Health Webinar, so you can begin your Healing Journey.⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠https://modernendocrinewellness.com/join-gut-health⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

On this episode, we define osteoporosis and describe its clinical presentations, underlying pathophysiology, and common etiologies. We compare and contrast the efficacy, safety profiles, and appropriate use of various antiresorptive and anabolic agents used in osteoporosis management. We also review current guidelines and evidence-based approaches for the prevention and treatment of osteoporosis, including pharmacological and nonpharmacological interventions. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922.   WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups.   Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that  kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life.     Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own  a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login   XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software.   Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.   We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say  metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/   XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool.         Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models.   Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy.   https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX   Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,.   Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity.   The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits.   The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age.   The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said.   The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias."   Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences.   Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative.   Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year.   "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives."   Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org.   "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us."   Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market.   About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.   With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.   Learn more at mannkindcorp.com.   About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing.   Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet.   Learn more at aemanncharities.org.   About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has

About Patrick Schinzel:Patrick Schinzel is the Chief Operations Officer at Strive Pharmacy, where he has been instrumental in driving operational excellence and patient-focused innovation since 2023. With over two decades of experience in pharmacy leadership, Patrick brings a deep understanding of both clinical care and business strategy. Before stepping into his current executive role, he served as a pharmacist at Strive Pharmacy and Walgreens, where he spent nearly 20 years ensuring top-quality patient care and operational efficiency. Beyond pharmacy, Patrick has also demonstrated entrepreneurial drive as the long-time owner of Potential Home Buyers LLC, a real estate venture he has led since 2008. He earned his PharmD and bachelor's in pharmaceutical sciences from South Dakota State University, following his studies at the University of Nebraska–Lincoln and Clarke Community. Based in Mesa, Arizona, Patrick combines his expertise in healthcare and business to advance Strive Pharmacy's mission of delivering accessible, personalized, and high-quality pharmaceutical care.Things You'll Learn:Usage analytics revealed five consistently effective testosterone formulations from 370 variations, enabling faster fulfillment, lower prices, and maintained clinical autonomy.A thoughtful cash-pay strategy can enhance affordability today, even as broader reimbursement for underserved populations remains a significant industry challenge.Proactive potency testing on sterile lines (including GLP-1s) goes beyond basic safety to verify therapeutic effectiveness.“Preferred” formulations can coexist with precision medicine, extracting bulk efficiencies without eliminating personalization.The next leap is software that coordinates interdepartmental nuance, paving the way for robotics to deliver true “lot size of one” at scale.Resources:Connect with and follow Patrick Schinzel on LinkedIn.Follow Clinical Architecture on LinkedIn and visit their website. Email Patrick here.

From Pharmacist to Real Estate Investor: Building True Wealth Through Commercial Real Estate.Dr. Tanh, PharmD, is a pharmacist turned real estate investor, host of the Wonton Wealth Podcast, and founder of Proton Capital. After earning his Doctorate of Pharmacy from the University of Cincinnati and pursuing a career in cardiology pharmacy, Tanh discovered his true passion—investing and building long-term wealth through real estate. What started with a single duplex in 2018 quickly grew into a thriving portfolio and a deep focus on commercial real estate. As the author of Value Over Volume: The Foundation of Commercial Real Estate Investing, Tanh now empowers others to achieve financial freedom, build meaningful relationships, and reclaim their most valuable asset—time. His journey proves that with education, discipline, and purpose, anyone can create lasting wealth beyond the 9-to-5 grind.Follow Tanh

On this episode, we discuss ulcerative colitis (UC) and describe its clinical presentations, underlying pathophysiology, and common etiologies. We evaluate current clinical guidelines and evidence-based strategies for managing UC. We also compare and contrast the efficacy, safety profiles, and appropriate use of available UC therapies, such as aminosalicylates, corticosteroids, immunomodulators, and biologics.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

In this episode of Skin Anarchy, Dr. Ekta Yadav sits down with Dr. Stephanie Redmond, PharmD, PhD, and founder of Dr. Stephanie's, to explore how pharmacology is transforming the world of supplements and functional medicine. With dual expertise in endocrinology and pharmacotherapy, Dr. Redmond offers a rare perspective on how medications, nutrients, and hormones intersect — and how precision-based formulation is reshaping metabolic health.After years in clinical practice, Dr. Redmond noticed a glaring gap: most supplements on the market are underdosed, underperforming, and poorly understood. Her approach flips the script — using clinically validated, therapeutic dosesof ingredients designed for real efficacy and safety. “It's not about marketing,” she explains. “It's about measurable results.”The conversation dives deep into her breakthrough innovations, including Purify Colostrum, developed using AI-assisted filtration to isolate bioactive glycoproteins compatible with the human body — delivering seven times more anti-inflammatory power than standard colostrum. She also shares insights on her GLP-1 support formulations, designed to complement popular medications like Ozempic by addressing nutrient depletion, digestion, and hormonal balance.Together, Dr. Ekta and Dr. Redmond unpack what ethical, evidence-based supplementation truly looks like — where pharmacology meets function, and science replaces hype.Tune in to hear how Dr. Stephanie Redmond is redefining modern supplementation and why, in today's world, foundational nutrition is no longer optional — it's essential.Learn more about Dr. Stephanie's on their website and social media!CHAPTERS:0:02 – Introduction & Guest Welcome1:01 – Dr. Redmond's Path from Pharmacy to Endocrinology2:18 – Bridging Medicine, Supplements & Pharmacology4:43 – The Role of Pharmacists in Holistic Care7:09 – The Gap in Supplement Education & Dosing8:58 – Colostrum: Nature's “First Milk” Explained11:05 – Human vs. Bovine Colostrum & Compatibility14:44 – Postpartum, Perimenopause & Hormonal Health19:01 – GLP-1 Support Supplements & Metabolic Health27:27 – The Future of Foundational Wellness & Supplement TestingPlease fill out this survey to give us feedback on the show!Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.